Elevance Health is a giant insurance middleman that handles health coverage for roughly 118 million Americans, similar to a tollbooth operator for medical visits and prescriptions.
It earns thin margins (net margin ~3%) on massive annual revenue of USD 199.12B, mostly from collecting fixed monthly premiums and paying out claims — recurring but low-margin fee-for-service money.
Its network of provider contracts and government contracts (Medicaid/Medicare) creates switching costs, but competitors like UnitedHealth Group and Centene can undercut prices or win those contracts, weakening the moat.
Five-factor rating
Buy (sector percentile 71) — value A, growth C, profitability C+, momentum C, revisions A-. Updated daily, sector-relative, identical for every user.
ELV Maintains 'Moderate Buy' Consensus Post-Earnings
23 brokerages average 'Moderate Buy', reinforcing post-earnings guidance raise
D1 -1.0% · +5d -10.4%
›7 waves of this story
2026-07-10 Multiple independent sources confirm ELV on the earnings calendar starting July 13, with market focus on its results.
2026-07-13 Multiple sources confirm earnings date approaching; Zacks notes weaker Health Benefits results and higher benefit expenses may weigh on earnings
2026-07-15 Q2 net income $1.45B, medical costs ease, full-year outlook raised
2026-07-15 Q2 adj EPS $7.45 beat; FY EPS raised to at least $27
2026-07-13 Zacks flags health benefits weakness and higher expenses ahead of July 15 report; multiple social sources note earnings season start for ELV
2026-07-15 Q2 net income $1.45B, medical costs ease, FY outlook raised
2026-07-15 Adj EPS $7.45 beat; FY EPS raised to ≥$27 on cost improvement
2026-07-17 Q2 beat and guidance raise, but stock fell sharply, contrasting with UNH.
ELV Maintains 'Moderate Buy' Consensus Post-Earnings
23 brokerages average 'Moderate Buy', reinforcing post-earnings guidance raise
D1 -1.0% · +5d -10.4%
›7 waves of this story
2026-07-10 Multiple independent sources confirm ELV on the earnings calendar starting July 13, with market focus on its results.
2026-07-13 Multiple sources confirm earnings date approaching; Zacks notes weaker Health Benefits results and higher benefit expenses may weigh on earnings
2026-07-15 Q2 net income $1.45B, medical costs ease, full-year outlook raised
2026-07-15 Q2 adj EPS $7.45 beat; FY EPS raised to at least $27
2026-07-13 Zacks flags health benefits weakness and higher expenses ahead of July 15 report; multiple social sources note earnings season start for ELV
2026-07-15 Q2 net income $1.45B, medical costs ease, FY outlook raised
2026-07-15 Adj EPS $7.45 beat; FY EPS raised to ≥$27 on cost improvement
2026-07-17 Q2 beat and guidance raise, but stock fell sharply, contrasting with UNH.
